sorry, we can't preview this file

...but you can still download (227.12 GB)

Histology dataset supporting paper "A preclinical randomized controlled multicenter trial of anti-IL-17A treatment for acute ischemic stroke"

Download (227.12 GB)
posted on 2023-01-12, 02:12 authored by Simon KochSimon Koch, Simon Koch, Mathias Gelderblom, Jan-Kolja Strecker, Carina Jørgensen, Lidia Garcia-Bonilla, Peter Ludewig, Ines S. Schädlich, Marius Piepke, Karoline Degenhardt, Christian Bernreuther, Hans Pinnschmidt, Thiruma Valavan Arumugam, Götz Thomalla, Cornelius Faber, Jan Sedlacik, Christian Gerloff, Jens Minnerup, Bettina Hjelm Clausen, Josef Anrather, Tim Magnus

This folder contains the raw histology data from the study "A preclinical randomized controlled multicenter trial of anti-IL-17A treatment for acute ischemic stroke". These data were used for counting of the infiltrating neutrophilic granulocytes.

See related materials in Collection at: 

Manuscript abstract

Multiple consensus statements have called for preclinical randomized controlled trials (pRCT) to improve translation in stroke research. We investigated the efficacy of an IL-17A neutralizing antibody in a multicenter pRCT using a murine ischemia reperfusion stroke model. Twelve week old, male C57BL/6 mice were subjected to 45 minutes of transient middle cerebral artery occlusion (tMCAO) in four centers. Mice were randomly assigned (1:1) to receive either an anti-IL-17A (500 µg) or isotype antibody (500 µg) intravenously one hour after reperfusion. The primary endpoint was infarct volume measured by MRI three days after tMCAO. Secondary analysis included mortality, neurological score, neutrophil infiltration and the impact of the gut microbiome on treatment effects. Out of 136 mice, 109 mice were included in the analysis of the primary endpoint. Mixed model analysis revealed that IL-17A neutralization significantly reduced infarct sizes (anti-IL-17A: 61.77 ± 31.04 mm3; IgG control: 75.66 ± 34.79 mm3; p=0.01). Secondary outcome measures showed a decrease in mortality (Hazard Ratio=3.43, 95% CI=1.157-10.18; p=0.04) and neutrophil invasion into ischemic cortices (anti-IL-17A: 7222 ± 6108 cells; IgG control: 28153 ± 23206 cells; p<0.01). There was no difference in Bederson score. The analysis of the gut microbiome showed significant heterogeneity between centers (R=0.78, p<0.001, n=40). Taken together, neutralization of IL-17A in a therapeutic time window resulted in a significant reduction of infarct sizes and mortality compared to isotype control. It suggests IL-17A neutralization as a potential therapeutic target in stroke.  


This work was supported by grants from Deutsche Forschungsgemeinschaft (KFO Immunostroke 2879: Project A1 (T.M. 4248778651), Project B3 (M.G. 428778375)), the Schilling foundation (T.M.) and the core unit PIX of the Interdisciplinary Center for Clinical Research Münster.

Decoding IL-17A-mediated influences on stroke recovery

Deutsche Forschungsgemeinschaft

Find out more...


Research Institution(s)

Department of Neurology, University Medical Center Hamburg-Eppendorf; Hamburg, Germany

Contact email

I confirm there is no human personally identifiable information in the files or description shared

  • Yes

I confirm the files and description shared may be publicly distributed under the license selected

  • Yes

Competing Interest Statement